Bavarian Nordic to Host First Half 2017 Results Conference Call

Bavarian Nordic to Host First Half 2017 Results Conference Call

ID: 557084

(Thomson Reuters ONE) -


COPENHAGEN, Denmark - August 18, 2017 - Bavarian Nordic A/S (OMX:  BAVA, OTC:
BVNRY) will announce its 2017 first half results on Friday, August 25, 2017.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST
(8:00 am EDT) on the same day to present the interim results followed by a Q&A
session.

Dial-in numbers for the conference call are: Denmark: +45 32 71 16 60, UK: +44
(0) 20 3427 1911,  USA: +1 646 254 3364. Participant code is 7659153.

A live and archived webcast of the call and relevant slides will be available at
http://bit.ly/2fJFsgP.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications.
Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone:
+1 978 341 5271

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, and therapeutic vaccines for HPV, HBV
and HIV. Additionally, in collaboration with the National Cancer Institute,
Bavarian Nordic has developed a portfolio of active cancer immunotherapies,
including PROSTVAC(®), which is currently in Phase 3 clinical development for
the treatment of advanced prostate cancer. The company has partnered with




Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more
information visit www.bavarian-nordic.com or follow us on Twitter
(at)bavariannordic.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via GlobeNewswire




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 18.08.2017 - 16:00 Uhr
Sprache: Deutsch
News-ID 557084
Anzahl Zeichen: 2681

contact information:
Town:

Kvistgård



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 305 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Bavarian Nordic to Host First Half 2017 Results Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von

Bavarian Nordic A/S (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Bavarian Nordic A/S



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z